According to the results of a clinical trial (NCT01536743) which evaluated the efficacy and safety of palbociclib (another CDK4/6 inhibitor) in recurrent ovarian cancer, CDK4/6 inhibition with Palbociclib showed single-agent activity and is well tolerated in heavily pretreated ovarian cancer patients, with 30% of patients were free from disease progression at 6 months after treatment 52. This evidence concerns the gene CDK4 and ovarian cancer.